Next week I’m lucky enough to be heading off to San Diego to attend the American Diabetes Association’s annual conference: the ADA Scientific Sessions. I’m attending as part of the #dedoc˚ voices program, as one of 12 diabetes advocates from around the globe who together will be trying to represent people who live with diabetes …
I wrote recently about re-usable pens (which I much prefer over the disposables). For years in Australia Novo Nordisk has provided two pens to use with their Penfill cartridges: NovoPen 4: 1U increments up to 60U/dose. NovoPen Echo: has memory of last dose size and time, 0.5U increments up to 30U. Of course, the older NovoPen …
In the last article I discussed what I think is a remarkable comparison between my recent personal data and the output of a 2019 CGM study of people without diabetes. At the end I showed a graph stretching over 20 years. It shows my HbA1c results over that time, overlaid with the TIR data from …
Further comparison with HCL and non-diabetic data Read More »
I’ve written multiple times about the benefits of using different ranges for Time In Range (see “Targets and Goals“). This is revisiting that topic in light of some recent experimental data. Like many this article has become quite long, but it’s split into sections: Terminology introduction, and choosing a new range based on published study …
I’ve mentioned previously a clinical trial I was involved in running, in which 20 people used AndroidAPS and research YpsoPumps. The next trial is now up and running. It’s called “CLOSE IT” (or sometimes CloseIt or Close-It) which stands for “Closed Loop Open SourcE In Type 1 diabetes”. No in case you’re wondering, I didn’t …
Ever since I wrote about the Anubis project (twice in 2021) I keep getting people assuming that I’m responsible for it. They send me requests for units, instructions as to how to make them themselves, etc. Just to be clear: I was one of the people involved in early testing of the units, and I …